SLUCare specialists in hematology, oncology and cellular therapy are committed to leadership in clinical research programs. As the faculty of Saint Louis University School of Medicine, our staff regularly conducts clinical trials of new medicines and technologies. The following studies are now seeking participants.
Defining How Patient BMI Influences the Response to Immunotherapy for Cancer
Dr. Ryan Teague
A study to determine how immunotherapy influences BMI in patients with any cancer planned to receive Pembrolizumab, Atezolizumab, Ipilimumab, Nivolumab, or Durvalumab
Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Alliance/ A051301 - Dr. Mark Fesler
A randomized double-blind phase III study of ibrutinib during and following autologous stem cell transplantation versus placebo in patients with relapsed or refractory diffuse large B-cell lymphoma of the activated B-cell subtype
Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
ECOG-ACRIN/ EA4151 - Dr. Mark Fesler
A randomized phase III trial of consolidation with autologous hematopoietic cell transplantation followed by maintenance rituximab vs. maintenance rituximab alone for patients with mantle cell lymphoma in minimal residual disease-negative first complete remission
A Study of Retreatment with Brentuximab Vedotin in Subjects with Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma
SeattleGenetics/ SGN35-028 - Dr. Mark Fesler
A phase 2, multicenter, single-arm study of retreatment with brentuximab vedotin in subjects with relapsed or refractory classic Hodgkin lymphoma (cHL) or CD30-expressing peripheral T cell lymphoma (PTCL)
Randomized, Open-Label, Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Best Available Therapy in Subjects with Relapsed/Refractory Myelofibrosis (TRANSFORM-2/M20-178)
AbbVie/ M20-178 - Dr. Abishek Chilkulwar
Navitoclax is an investigational drug (not yet approved) being developed for the treatment of Myelofibrosis (MF). The study has 2 arms - A and B. In Arm A, participants will receive navitoclax in combination with ruxolitinib. In Arm B, participants will receive the best available therapy (BAT) for MF. Adult participants with a diagnosis of relapsed/refractory (R/R) MF will be enrolled.
Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
Merck/ LEAP-012: MK7902-012 - Dr. John Richart
A phase 3 multicenter, randomized, double-blinded, active-controlled, clinical study to evaluate the safety and efficacy of lenvatinib (E7080/MK-7902) with pembrolizumab (MK-3475) in combination with transarterial chemoembolization (TACE) versus TACE in participants with incurable/non-metastatic hepatocellular carcinoma
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
SeattleGenetics / SGN35-031 - Dr. Mark Fesler
Participants in this study will have diffuse large B-cell lymphoma (DLBCL) that has come back or not gotten better with treatment. The trial will study whether brentuximab vedotin plus two drugs works better to treat this type of cancer than the two drugs alone.
Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
Incyte/GRAVITAS-309 - Dr. Nabeel Rajeh
The purpose of this study is to assess the efficacy and safety of itacitinib in combination with corticosteroids as first-line treatment for moderate or severe chronic graft-versus-host disease (cGVHD).
A five-year longitudinal observational study of the natural history and management of patients with hepatocellular carcinoma.
Target PharmaSolutions/TargetHCC - Dr. John Richart
TARGET-HCC is a longitudinal, observational study of patients being managed for HCC in usual clinical practice. TARGET-HCC will create a research registry of participants with HCC within academic and community real-world practices in order to assess the safety and effectiveness of the entire spectrum of current and future therapies across diverse populations.